EVOTEC SE INH O.N.
Commented by Fabian Lorenz on February 4th, 2026 | 08:50 CET
Yesterday +10%! Top news drives shares of Evotec, Novo Nordisk, and CHAR Technologies!
Evotec shares jumped, climbing more than 10% as analysts pushed the stock higher. Does this signal that the turnaround is finally happening, or does Deutsche Bank still have the final say? Strong news also for CHAR Technologies: the Canadian company is launching commercialization of its unique technology for producing biochar and renewable natural gas substitutes from biogenic waste materials. For the expansion, it has secured strong partners, including steel giant ArcelorMittal and the Canadian BMI Group. And what is Novo Nordisk doing? The Danish company presented positive study results for its successor to Wegovy. However, analysts are not exactly thrilled.
Read
Commented by André Will-Laudien on February 4th, 2026 | 07:10 CET
Starting signal! Biotech sector benefits from rotation! Keep an eye on Evotec, Bayer, Vidac Pharma, and BioNTech
The stock market has started 2026 on a positive note. The mining and commodities sector recently proved that return opportunities are not limited to the technology sector, with several stocks doubling in price and a few even increasing tenfold. A breath of fresh air is needed, because other sectors also want to enjoy the stock market spring. Life science stocks have indeed taken a break for almost three years. But now they are back! After a long period of silence, selected companies are showing the first signs of a technical recovery. For investors with a penchant for opportunities and timing, now is the time to rethink old strategies and realign portfolios. In cancer research, recent breakthroughs in personalized immunotherapies have significantly increased the prospects of success for clinical trials. We take a closer look.
Read
Commented by Armin Schulz on February 3rd, 2026 | 07:05 CET
Zinc boom, turnaround, and biotech growth: How to profit with Pasinex Resources, Puma, and Evotec
In volatile markets, investors are looking for exceptional opportunities. Three companies stand out in this regard. A commodities company with exceptional zinc projects, a sporting goods manufacturer undergoing radical transformation, and a biotech pioneer with a unique platform model. The combination of momentum, strategic turnaround, and long-term growth promises attractive return opportunities. We analyse the promising prospects of Pasinex Resources, Puma, and Evotec.
Read
Commented by Fabian Lorenz on January 29th, 2026 | 07:00 CET
Puma takeover is becoming more concrete! Should investors buy Evotec and Silver Viper shares next?
Takeover speculation has been swirling around Puma for some time. Now it has become more tangible: Anta has secured a 29% stake in the German sporting goods group, paying EUR 35 per share. However, the euphoria on the stock market is limited. Are there better opportunities for investors to profit from takeover speculation? One candidate in the hot silver market is Silver Viper. The Company is pushing ahead with exciting projects in Mexico. Its recent capital increase met with strong demand, and a financially powerful potential buyer already has a foot in the door. And what about Evotec? The perennial takeover candidate is still not gaining momentum. That said, the biotech company is benefiting from the sale of one of its own holdings, which is expected to bring in around USD 160 million.
Read
Commented by Armin Schulz on January 21st, 2026 | 08:25 CET
Evotec, A.H.T. Syngas Technology, Deutsche Telekom: Three stocks on the verge of a decisive turning point?
Germany's economy is at a crossroads. Its old strengths are crumbling, but this is precisely what opens up opportunities for companies that are strategically realigning themselves. The key to success is not simple adaptation, but a fundamental turnaround. Three decisive paths are emerging: disruptive innovation in the biotech industry, energy production and decarbonization, and the development of sovereign digital networks. Today, we take a closer look at three companies and analyze which stocks are on the verge of a turnaround: Evotec, A.H.T. Syngas Technology, and Deutsche Telekom.
Read
Commented by André Will-Laudien on January 2nd, 2026 | 07:05 CET
Attention - fasten your seatbelts! 2026 could be a rocket launch for Novo Nordisk, Evotec, Bayer, and Vidac Pharma
The stock market is starting the new year 2026 in a buoyant mood. The mining and commodities sector showed that it is not only possible to make money with tech stocks, with almost every stock doubling in value, and some even increasing tenfold. The coming year, however, could bring yet another shift in perspective. The biotech sector has been quiet for quite some time, but some of the protagonists in our selection are showing, in part, significant technical base formations. For risk-aware investors, it may be time to reshuffle more decisively and realign portfolios. Come in and find out!
Read
Commented by Carsten Mainitz on December 30th, 2025 | 11:15 CET
Stock Picking Alert! Power Metallic Mines – Set to Double? Puma and Evotec as Promising Turnarounds?
The 2025 stock market year has produced many winners, but also some losers. Bullish commodity markets and project progress led to a jump in the share price of Canadian commodity company Power Metallic Mines at the beginning of the year. In December, the share price corrected, but the upward trend quickly resumed, buoyed by good drilling results. The Canadian company holds one of the largest polymetallic deposits in North America, which has attracted many well-known investors this year. It is also worth taking a look at turnaround bets with takeover potential, such as Evotec and Puma.
Read
Commented by Fabian Lorenz on December 29th, 2025 | 07:00 CET
Comeback 2026! Tenfold potential? Evotec, Gerresheimer, and Desert Gold shares!
Looking for a potential ten-bagger in the gold sector? Analysts believe this could be possible for Desert Gold. The recently published PEA for the flagship gold project is triggering new price speculation. This could finally end the years-long sideways trend and allow the stock to take off. Investors had hoped for a turnaround in 2025 at Evotec. Instead, the biotech stock continued its downward trend. The strategy of the new management team does not appear to have convinced major shareholders either. Gerresheimer was an unpleasant surprise in 2025. At the turn of the year, the Company is at least engaged in damage control. But how significant is the loss of confidence?
Read
Commented by Carsten Mainitz on December 17th, 2025 | 07:35 CET
Winners for 2026: RZOLV Technologies, Evotec, Mutares have what it takes – which developments are crucial?
The 2025 stock market year was full of exciting developments. Bull markets in commodities, interest rate cuts, and geopolitical tensions. However, some companies, such as Evotec, had to deal with many home-grown problems and lagged behind the positive performance of the overall market. Mutares saw its coffers fill up, but its share price could have done better this year. Next year could be very successful for RZOLV Technologies. The Canadians are solving a major problem in gold mining.
Read
Commented by Fabian Lorenz on December 15th, 2025 | 07:25 CET
Alarm bells ringing at Evotec! BioNTech and Vidac Pharma achieve success in the fight against cancer! Analysts recommend buying!
Alarm bells are ringing at Evotec. A major shareholder has completely withdrawn from the German biotech company. The security is trading at 2016 levels. Vidac Pharma, on the other hand, has reached a milestone. In the EU, the Phase 2b clinical trial for the ointment Tuvatexib (VDA1102) against a particularly active, fast-growing precursor of skin cancer can begin. BioNTech is also continuing the fight against cancer. Initial results from the global Phase 2 trial of the non-specific antibody candidate Pumitamig showed encouraging anti-tumor activity in advanced triple-negative breast cancer. Analysts recommend buying shares in Vidac and BioNTech.
Read